TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11145360

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 195

Group type: COMPARATOR
Intervention: Fluoride or chlorhexidine varnish treatment
Number of subjects: 195
Study: 8598866

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ticlopidine plus aspirin)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin)
Number of subjects: 517
Study: 1412114

Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 42 degrees C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment at 31 degrees C
Number of subjects: 10
Study: 3871233

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: amoxicillin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: cyclacillin
Number of subjects: 38
Study: 30121789

Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Endurance training (EG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study: 29101421

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (INT)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Standard glycaemic control (STD)
Number of subjects: 1033
Study: 26945662

Group type: EXPERIMENTAL
Intervention: 5 mg Finasteride daily for 2 weeks before TURP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 5 mg Finasteride daily for 4 weeks before TURP
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 65
Study: 24626137

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI; 10 ± 0.5° C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Thermoneutral water immersion (TNI; 34 ± 0.5° C)
Number of subjects: 7
Study: 22613412

Group type: EXPERIMENTAL
Intervention: Lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l) for 3 months prior to surgery
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lanreotide treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Trans-sphenoidal surgery after lanreotide treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 49
Study: 20107463

Group type: EXPERIMENTAL
Intervention: MEND Program (intervention group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waiting list control (control group)
Number of subjects: 116
Study: 17980395

Group type: EXPERIMENTAL
Intervention: High selenium levels
Number of subjects: 172

Group type: COMPARATOR
Intervention: Low selenium levels
Number of subjects: 172
Study: 15892286

Group type: EXPERIMENTAL
Intervention: Clomiphene plus Yijing Huoxue Cuyun Decoction (YHCD)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Clomiphene plus YHCD
Number of subjects: 118

Group type: COMPARATOR
Intervention: Clomiphene plus estradiol valerate
Number of subjects: 118
Study: 12645445

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study: 10807025

Group type: EXPERIMENTAL
Intervention: Treatment intensity for the last year and month of life for deceased clients
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Overall treatment intensity for all clients
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Treatment intensity in the last month of life for all age groups
Number of subjects: 278
Study: 8858555

Group type: EXPERIMENTAL
Intervention: Beverage instructions and content (alcoholic vs non-alcoholic beer)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 132
Study: 1644012

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 48
Study: 6324526

Group type: EXPERIMENTAL
Intervention: Photocoagulation therapy (mild treatment with panretinal, focal or both techniques using short‐pulse, small‐spot xenon arc or argon laser methods)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control eyes (not treated with photocoagulation)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Patients with mild non‐proliferative changes
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Patients with moderate-severe non‐proliferative changes
Number of subjects: 211
Study: 31654891

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5mug
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5mug
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 29986507

Group type: EXPERIMENTAL
Intervention: Fuzzy logic-based estimation mechanism for IoT service quality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomization Test (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Test in Steps (STS)
Number of subjects: 0
Study: 26812052

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg per day
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg per day (females)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo (females)
Number of subjects: 326
Study: 24445121

Group type: EXPERIMENTAL
Intervention: Topically applied heat at 42°C for 30 seconds daily with allantoin lotion formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topically applied heat at 42°C for 30 seconds daily with allantoin gel formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site with no active and no heat
Number of subjects: 0
Study: 23229961

Group type: EXPERIMENTAL
Intervention: Telephone‐initiated adherence support by pharmacists following computer‐generated missed refill alerts.
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 265
Study: 20795810

Group type: EXPERIMENTAL
Intervention: Personalized materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-personalized materials
Number of subjects: 0
Study: 17337493

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 315

Group type: COMPARATOR
Intervention: Subcutaneous insulin injection
Number of subjects: 315
Study: 15721015

Group type: EXPERIMENTAL
Intervention: Roxithromycin (400 mg daily for 4 weeks)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Macrolide treatment (Roxithromycin)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Seropositive untreated group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Seronegative and macrolide-treated group
Number of subjects: 97

Group type: COMPARATOR
Intervention: C. pneumoniae seropositivity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Number of subjects: 97
Study: 11574432

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Multiple daily insulin injection (MDI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 27

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 27
Study: 9780764

Group type: EXPERIMENTAL
Intervention: Desflurane (3% inspired concentration)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Isoflurane (0.5% inspired concentration)
Number of subjects: 98
Study: 8092865

Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 14

Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 14
Study: 3103424

Group type: EXPERIMENTAL
Intervention: Red pepper (0.1-1.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black pepper (1.5 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (655 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study: 31757568

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 30253174

Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study: 27448942

Group type: EXPERIMENTAL
Intervention: Potassium Chloride (KCl) for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium Magnesium Citrate (KMgCit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium Citrate (KCit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24602708

Group type: EXPERIMENTAL
Intervention: Short laparoscopic training session
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 205
Study: 23347808

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.1μg/kg/min for 10 minutes prior to induction and 0.7μg/kg/hour until 10 minutes before the end of the operation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion (control group).
Number of subjects: 60
Study: 21643719

Group type: EXPERIMENTAL
Intervention: Attention directed to multiple competing stimulus items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous presentation of multiple items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention directed to single items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional status of items
Number of subjects: 0
Study: 18372428

Group type: EXPERIMENTAL
Intervention: 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days
Number of subjects: 12
Study: 16490976

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) applied before skin closure
Number of subjects: 107

Group type: COMPARATOR
Intervention: No Povidone-iodine (control group)
Number of subjects: 107
Study: 12943960

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30-60 mg/daily) in addition to cognitive-behavioral detoxification protocol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cognitive-behavioral detoxification protocol (non-pharmacological approach)
Number of subjects: 54
Study: 10843747

Group type: EXPERIMENTAL
Intervention: Intravenous catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Needle stick (control)
Number of subjects: 20
Study: 9150698

Group type: EXPERIMENTAL
Intervention: 300 micrograms C-type natriuretic peptide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 150 micrograms C-type natriuretic peptide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8468438

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg three times daily)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Dothiepin (75 mg daily for first two weeks, then 150 mg thereafter)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Dothiepin (75-150 mg)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 345
Study: 6222700

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids (Triamcinolone acetonide at 0.63 mg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intralesional corticosteroids (Betamethasone phosphate at 3.0, 1.5, and 0.75 mg/mL)
Number of subjects: 0
Study: 30932903

Group type: EXPERIMENTAL
Intervention: tDCS (M1‐SO montage, anode ipsilesional, 5×7 cm electrodes, 2 mA, 20 mins) prior to robotic upper‐limb training (12 weeks; 36 sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham tDCS prior to robotic upper‐limb training (12 weeks; 36 sessions)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (tDCS and sham)
Number of subjects: 82
Study: 29731416

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise-induced increases in IL-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 inhibition
Number of subjects: 0
Study: 27553622

Group type: EXPERIMENTAL
Intervention: EmbryoScope™
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard embryology
Number of subjects: 48
Study: 25657364

Group type: EXPERIMENTAL
Intervention: Intervention B (supervised hands-on education, peer assessment/education, and simulated scenario counseling real asthma patients)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Intervention A (supervised hands-on education and peer assessment/education)
Number of subjects: 109
Study: 22954893

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2496
Study: 19446324

Group type: EXPERIMENTAL
Intervention: Early exercise and mobilisation (physical and occupational therapy) during periods of daily interruption of sedation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Daily interruption of sedation with therapy as ordered by the primary care team
Number of subjects: 104
Study: 17624914

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 16469079

Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 0
Study: 15383514

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 180

Group type: COMPARATOR
Intervention: Prudent diet (control)
Number of subjects: 180
Study: 11259933

Group type: EXPERIMENTAL
Intervention: High voltage stimulation (HVS); 100 V, doubled‐peak monophasic impulses of 0.1 ms duration and 100 Hz frequency.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Topically applied medicine (Control group B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Unna's boot (Control group C)
Number of subjects: 79
Study: 8686328

Group type: EXPERIMENTAL
Intervention: Wobenzym
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1647193

Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms kg‐1 body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Granisetron and Lorazepam (in combination)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6856226

Group type: EXPERIMENTAL
Intervention: Combination of 0.5% bupivacaine, dilute epinephrine, and methylergonovine maleate (randomized drug regimens)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Fentanyl (nonrandomized selected group)
Number of subjects: 215
Study: 30561134

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 165
Study: 25419583

Group type: EXPERIMENTAL
Intervention: Alcohol + Tobacco Counseling (ATC)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Tobacco-Only Counseling (TOC)
Number of subjects: 1948

Group type: EXPERIMENTAL
Intervention: ATC
Number of subjects: 1948

Group type: COMPARATOR
Intervention: TOC
Number of subjects: 1948
Study: 23406294

Group type: EXPERIMENTAL
Intervention: High quantity and quality of participation
Number of subjects: 179

Group type: COMPARATOR
Intervention: Low quantity or quality of participation
Number of subjects: 179
Study: 23550422

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and extended release nicotinic acid 1G
Number of subjects: 216
Study: 18381377

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells (BMC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 47
Study: 16644639

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12792352

Group type: EXPERIMENTAL
Intervention: Switch to combivir (zidovudine/lamivudine) and abacavir
Number of subjects: 37

Group type: COMPARATOR
Intervention: Continued treatment with stavudine and/or protease inhibitor
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Switch to combivir/abacavir
Number of subjects: 37
Study: 10857179

Group type: EXPERIMENTAL
Intervention: Sentinel node dissection (SLND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical lymph node dissection
Number of subjects: 0
Study: 8864730

Group type: EXPERIMENTAL
Intervention: 1-day chemoprophylaxis with clindamycin-cefonicid
Number of subjects: 162

Group type: COMPARATOR
Intervention: 3-day chemoprophylaxis with clindamycin-cefonicid
Number of subjects: 162
Study: 1515247

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Number of subjects: 63
Study: 6338767

Group type: EXPERIMENTAL
Intervention: MDI plus aerochamber (AC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDI plus AC
Number of subjects: 12
Study: 30529387

Group type: EXPERIMENTAL
Intervention: Sorafenib + concurrent transarterial chemoembolization (cTACE)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Sorafenib + cTACE (≥2 sessions)
Number of subjects: 339
Study: 28777900

Group type: EXPERIMENTAL
Intervention: Staged compression protocol (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Linear compression protocol (n=50)
Number of subjects: 100
Study: 26598748

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 25053385

Group type: EXPERIMENTAL
Intervention: Phosphoramide mustard (PAM) measured as N‐[2‐(2‐oxazolidonyl)ethyl]‐valyl Hb (OzVal‐Hb)
Number of subjects: 12
Study: 22031509

Group type: EXPERIMENTAL
Intervention: Salivary cortisol measured in response to mental stressors (5-min Stroop task and 5-min mirror tracing task)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Cortisol stress reactivity
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Blood pressure measured at study entry and at 3-year follow-up
Number of subjects: 479
Study: 18819705

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 746

Group type: COMPARATOR
Intervention: Glimepiride 8 mg
Number of subjects: 746
Study: 17180281

Group type: EXPERIMENTAL
Intervention: HALO360 system with 14 J/cm2 for 4 applications
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HALO360 system with 12 J/cm2 for 2 applications
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HALO360 system with 10, 12, or 14 J/cm2 for two, three, or four applications
Number of subjects: 8
Study: 15826228

Group type: EXPERIMENTAL
Intervention: Memory cue matching the shape containing the target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory cue containing a distractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invalid memory cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No memory cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consecutive trials with memory cues
Number of subjects: 0
Study: 11572297

Group type: COMPARATOR
Intervention: Z100 control
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glass-ionomer liner on the cavosurface margin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Compomer/hybrid combination
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Flowable/hybrid combination
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Packable composite
Number of subjects: 70
Study: 9554765

Group type: EXPERIMENTAL
Intervention: Micro Stent I
Number of subjects: 93

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 93
Study: 7933494

Group type: EXPERIMENTAL
Intervention: Hypertonic lactated Ringer's solution (HLS) with sodium of 213 mEq.l‐1
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular lactated Ringer's solution (control)
Number of subjects: 14
Study: 3230151

Group type: EXPERIMENTAL
Intervention: Immediate-release verapamil (80 to 120 mg three times a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30630788

Group type: EXPERIMENTAL
Intervention: Compound shuanghua tablets combined with western drug therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine western drug therapy
Number of subjects: 140
Study: 28610669

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg three times daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 68
Study: 26209542

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 23902840

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 µg/d plus aminophylline tablet (0.1 g, 3 times/day, oral administration)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Inhaled budesonide 320 µg/day plus formoterol 9 µg/day
Number of subjects: 280
Study: 20876500

Group type: EXPERIMENTAL
Intervention: Carotid Stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 0
Study: 18254672

Group type: COMPARATOR
Intervention: D‐Stat Dry (wound dressing)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Mechanical closure devices (Angio‐Seal and StarClose)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Angio‐Seal
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 852
Study: 17036485

Group type: EXPERIMENTAL
Intervention: Normal acupuncture
Number of subjects: 152

Group type: COMPARATOR
Intervention: Shallow needling with short-needle
Number of subjects: 152
Study: 14608586

Group type: EXPERIMENTAL
Intervention: Support for people after suicide attempt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term lithium treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of different strategies in a multi-level approach
Number of subjects: 0